Therapeutic potential of an anaerobic cultured human intestinal microbiota, ACHIM, for treatment of IBS

Publication date: Available online 29 April 2019Source: Best Practice & Research Clinical GastroenterologyAuthor(s): P. Benno, E. Norin, T. Midtvedt, P.M. HellströmAbstractBy administering an anaerobic cultivated human intestinal microbiota (ACHIM) via upper gastrointestinal route using endoscopy we aimed to rectify intestinal dysbiosis and simultaneously achieve a treatment response in IBS patients. The study population fulfilled the Rome III IBS criteria and comprised 50 patients. During 10 days, patients recorded the irritable bowel syndrome symptom severity scale (IBS-SSS) along with the Bristol stool scale and number of stools/day. The enrolled patients were categorized as follows: 37 with diarrhea, 5 with constipation and 8 with mixed symptoms. The treatment response showed reduction in a majority of patients, 32 of which with 50-point reduction of IBS-SSS and 21 with a 100-point IBS-SSS reduction. The percentage improvement was 36 (23–49) and 28 (18–38) for women and men respectively. Short-chain fatty acids were not changed. We consider fecal microbiota transplantation in the form of ACHIM as an option for the future therapeutic armamentarium in IBS.Registered trialwww.clinicaltrials.gov NCT02857257.
Source: Best Practice and Research Clinical Gastroenterology - Category: Gastroenterology Source Type: research